Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • capricy
    Senior Member
    • Apr 2012
    • 125

    #1

    DEXseq: different usage for the shared exon

    I read the DEXseq paper (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460195/) and found that the examples of the differentially used exons (chimpanzee data ) are all existing/missing in some isoforms.

    My results revealed some differentially exons are shared in all the isoforms. How should I interpret this kind results?

    An example is shown in the attached cartoon. That is, two isoforms: "a" and "b", exist for this gene. The red exon was the differentially used exon based on the calculated p-value between three tissues, brain,intestine, and liver.

    Another question about the output: what does it mean by "normalized accounts" and "fitted expression"? Normalized against what?

    I have a gene with final baseMean of 73, and in the plotDEXseq graph, the corresponding values of the fitted expression were 40, 50, and over 100. How do those values relate to the baseMean?

    Thank you very much for any inputs.
    Attached Files
  • areyes
    Senior Member
    • Aug 2010
    • 165

    #2
    Hi capricy (and sorry for the late reply):

    The counts are normalized for sequencing depth. The "fitted splicing", are the fitted values from a generalised linear model corresponding to "exon usage levels". So, imagine you have a gene that is differentially expressed and it has also exons with differential inclusion. The "fitted splicing" will remove those effects caused by the difference in expression levels, and only keep those that are due to differences in exon usage. The mean base is simply the mean of the counts across all the samples.

    Best
    Alejandro

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
      by SEQadmin2



      Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

      Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
      ...
      10-14-2026, 09:55 AM
    • SEQadmin2
      New Genomics Technologies Take Aim at Long-Standing Limits
      by SEQadmin2


      Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

      We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
      ...
      09-28-2026, 10:25 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Yesterday, 11:13 AM
    0 responses
    19 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, Yesterday, 10:48 AM
    0 responses
    18 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-15-2026, 10:52 AM
    0 responses
    36 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-14-2026, 05:39 AM
    0 responses
    42 views
    0 reactions
    Last Post SEQadmin2  
    Working...